Dutasteride, already on the market, cuts cancer risk by about 25%, researchers say.
研究者称，度他雄胺，一种已上市的药物，可减少25%患癌症风险。
Dutasteride therapy, as compared with placebo, resulted in a reduction in the rate of acute urinary retention (1.6% vs. 6.7%, a 77.3% relative reduction).
与安慰剂相比，度他雄胺疗法使急性尿潴留的发生率下降(1.6%对6.7%，相对降幅为77.3%)。
In similar fashion, the REDUCE trial assessed the daily use of dutasteride, 0.5 mg, vs placebo for 4 years, for the reduction in the risk for prostate cancer in men at least 50 years of age.
同样的方法，PCPT实验评价比较了每天服用0.5mg非那雄胺和安慰剂，连续4年。男性至少50岁的前列腺癌患病的风险减少。
In similar fashion, the REDUCE trial assessed the daily use of dutasteride, 0.5 mg, vs placebo for 4 years, for the reduction in the risk for prostate cancer in men at least 50 years of age.
同样的方法，PCPT实验评价比较了每天服用0.5mg非那雄胺和安慰剂，连续4年。男性至少50岁的前列腺癌患病的风险减少。
应用推荐